SEARCH:   Advanced

Blood, 15 September 2007, Vol. 110, No. 6, pp. 1713-1722. Prepublished online as a Blood First Edition Paper on May 31, 2007; DOI 10.1182/blood-2007-03-055749. This Article Full Text (PDF) Supplemental Appendices Erratum (v111,p4830) All Versions of this Article: blood-2007-03-055749v1 110/6/1713    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Olsen, E. Articles by Whittaker, S. Search for Related Content PubMed PubMed Citation Articles by Olsen, E. Articles by Whittaker, S. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 6, 2007 Accepted April 18, 2007 Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Elise Olsen*, Eric Vonderheid, Nicola Pimpinelli, Rein Willemze, Youn Kim, Robert Knobler, Herschel Zackheim, Madeleine Duvic, Teresa Estrach, Stanford I Lamberg, Gary Wood, Reinhard Dummer, Annamari Ranki, Gunter Burg, Peter Heald, Mark Pittelkow, Maria-Grazia Bernengo, Wolfram Sterry, Liliane Laroche, Franz Trautinger, and Sean Whittaker Department of Medicine, Divisions of Dermatology & Oncology, Duke University Medical Center, Durham, NC, United States Department of Dermatology, Johns Hopkins University, Baltimore, MD, United States Department of Dermatological Sciences, University of Florence, Florence, Italy Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands Department of Dermatology, Stanford University Medical Center, Stanford, CA, United States Department of Dermatology, University of Vienna, Vienna, Austria Department of Dermatology, University of California at San Francisco, San Francisco, CA, United States Department of Dermatology, University of Texas at Houston, Houston, TX, United States Department of Dermatology, University of Barcelona, Barcelona, Spain Department of Dermatology, University of Wisconsin, Madison, WI, United States Deparment of Dermatology, University Hospital Zurich, Zurich, Switzerland Department of Dermatology and Venereal Diseases, Helsinki University Hospital, Helsinki, Finland Department of Dermatology, University Hospital Zurich, Zurich, Switzerland Department of Dermatology, Yale University, New Haven, CT, United States Department of Dermatology, Mayo Clinic, Rochester, MN, United States Department of Dermatology, University of Turin, Turin, Italy Department of Dermatology, Charite, Humboldt University, Berlin, Germany Department of Immuno-Dermatology, Hospital Avicenne - University of Paris XIII, Paris, France Skin Tumour Unit, St . John's Institute of Dermatology, St. Thomas' Hospital, London, United Kingdom * Corresponding author; email: olsen001{at}mc.duke.edu. The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for Cutaneous T-cell Lymphoma. (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sezary Syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain variables that currently impede effective inter-institution and inter-investigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision pertains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Watch out, MF! Dan L. Longo Blood 2007 110: 1708-1709. [Full Text] [PDF] This article has been cited by other articles: H. M. Prince, S. Whittaker, and R. T. Hoppe How I treat mycosis fungoides and Sezary syndrome Blood, November 12, 2009; 114(20): 4337 - 4353. [Abstract] [Full Text] [PDF] W. Kempf "Cutaneous T-Cell Lymphoma": Cutaneous TNMania in Cutaneous Lymphomas--Reply Arch Dermatol, July 1, 2009; 145(7): 843 - 843. [Full Text] [PDF] T. Krejsgaard, C. S. Vetter-Kauczok, A. Woetmann, H. Kneitz, K. W. Eriksen, P. Lovato, Q. Zhang, M. A. Wasik, C. Geisler, E. Ralfkiaer, et al. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma Blood, June 4, 2009; 113(23): 5896 - 5904. [Abstract] [Full Text] [PDF] E. Kennah, A. Ringrose, L. L. Zhou, S. Esmailzadeh, H. Qian, M.-w. Su, Y. Zhou, and X. Jiang Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells Blood, May 7, 2009; 113(19): 4646 - 4655. [Abstract] [Full Text] [PDF] R. Willemze, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv115 - iv118. [Full Text] [PDF] P. Chandra, J. A. Plaza, Z. Zuo, A. H. Diwan, H. Koeppen, M. Duvic, L. J. Medeiros, and V. G. Prieto Clusterin Expression Correlates With Stage and Presence of Large Cells in Mycosis Fungoides Am J Clin Pathol, April 1, 2009; 131(4): 511 - 515. [Abstract] [Full Text] [PDF] R. van Doorn, M. S. van Kester, R. Dijkman, M. H. Vermeer, A. A. Mulder, K. Szuhai, J. Knijnenburg, J. M. Boer, R. Willemze, and C. P. Tensen Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome Blood, January 1, 2009; 113(1): 127 - 136. [Abstract] [Full Text] [PDF] S. O. Arulogun, H. M. Prince, J. Ng, S. Lade, G. F. Ryan, O. Blewitt, and C. McCormack Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation Blood, October 15, 2008; 112(8): 3082 - 3087. [Abstract] [Full Text] [PDF] M. C. Picchio, E. Scala, D. Pomponi, E. Caprini, M. Frontani, I. Angelucci, A. Mangoni, C. Lazzeri, M. Perez, D. Remotti, et al. CXCL13 Is Highly Produced by Sezary Cells and Enhances Their Migratory Ability via a Synergistic Mechanism Involving CCL19 and CCL21 Chemokines Cancer Res., September 1, 2008; 68(17): 7137 - 7146. [Abstract] [Full Text] [PDF] C. E. Introcaso, E. J. Kim, J. Gardner, J. M. Junkins-Hopkins, C. C. Vittorio, and A. H. Rook CD8+ Epidermotropic Cytotoxic T-Cell Lymphoma With Peripheral Blood and Central Nervous System Involvement Arch Dermatol, August 1, 2008; 144(8): 1027 - 1029. [Abstract] [Full Text] [PDF] B. F. Chong, A. J. Wilson, H. M. Gibson, M. S. Hafner, Y. Luo, C. J. Hedgcock, and H. K. Wong Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Clin. Cancer Res., February 1, 2008; 14(3): 646 - 653. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020